Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261573 | 0.79 | NR3C2 (0.59) | NR3C2PGRRAF1BRAFCYP11B1 | |
| SCHEMBL4258401 | 0.79 | ACLY (0.48) | NR3C2PGRRAF1BRAFCYP11B1 | |
| SCHEMBL4259454 | 0.77 | PDE3B (0.49) | NR3C2PGR | |
| SCHEMBL4273023 | 0.76 | PARP1 (0.56) | NR3C2PARP1HTR1ADRD2 | |
| SCHEMBL4271537 | 0.76 | NR3C2 (0.52) | NR3C2PARP1RAF1BRAFDRD2 | |
| SCHEMBL13932086 | 0.76 | NR3C2 (0.52) | NR3C2PARP1RAF1BRAFDRD2 | |
| SCHEMBL4257240 | 0.75 | NR3C2 (0.57) | NR3C2PGR | |
| SCHEMBL4264623 | 0.73 | MMP12 (0.58) | NR3C2PGRDRD2 | |
| SCHEMBL4261319 | 0.72 | PKM (0.50) | NR3C2PGRRAF1BRAF | |
| SCHEMBL4049030 | 0.69 | MMP12 (0.54) | NR3C2PGRPARP1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| CN-101365696-A | Compounds and compositions as modulators of steroid hormone nuclear receptors | IRM LLC (BM) | 2009-02-11 | — | — | CN | claimed |
| JP-2008508314-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1778242-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015259-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | claimed |
| EP-2841471-B1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | GRACE W R & CO (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190153135-A1 | Activator Compositions, Their Preparation, And Their Use In Catalysts | GRACE W R & CO (US) | 2019-05-23 | — | — | US | disclosed |
| US-10221264-B2 | Activator compositions, their preparation, and their use in catalysts | W. R. GRACE & CO.-CONN. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150105238-A1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | W. R. GRACE & CO.-CONN. | 2015-04-16 | — | — | US | disclosed |
| EP-2643366-B1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS | ALBEMARLE CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8895465-B2 | Activator compositions, their preparation, and their use in catalysis | ALBEMARLE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2643366-A2 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS | Albemarle Corporation (US) | 2013-10-02 | — | — | EP | disclosed |
| US-6403732-B2 | COORDIATION CATALSYTS OF ORGANOBORANES AND METALLOCENES FOR ADDITION POLYMERIZATION | NORTHWESTERN UNIVERSITY | 2002-06-11 | — | — | US | disclosed |
| US-6388114-B1 | ORGANOMETALLIC COMPOUND; SOLVENT SOLUBILITY; COORDINATION POLYMERIZATION CATALYST | NORTHWESTERN UNIVERSITY | 2002-05-14 | — | — | US | disclosed |
| WO-2002020156-A2 | STABLE CATALYSTS AND CO-CATALYST COMPOSITIONS FORMED FROM HYDROXYALUMINOXANE AND THEIR USE | ALBEMARLE CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| US-20010034424-A1 | Organo-lewis acids of enhanced utility, uses thereof, and products based thereon | ENERGY, UNITED STATES DEPARTMENT OF | 2001-10-25 | — | — | US | disclosed |
| US-6291695-B1 | AS COCATALYSTS IN USED IN POYMERIZATION REACTIONS | NORTHWESTERN UNIVERSITY | 2001-09-18 | — | — | US | disclosed |
| US-6262200-B1 | CONTACTING OLEFINIC MONOMER OR MONOMERS WITH POLYMERIZATION CATALYST COMPLEX TO OBTAIN HOMO-OR COPOLYMER | NORTHWESTERN UNIVERSITY | 2001-07-17 | — | — | US | disclosed |
| US-6218332-B1 | AS POLYMERIZATION COCATALYSTS | NORTHWESTERN UNIVERSITY | 2001-04-17 | — | — | US | disclosed |
| US-6160145-A | Transition metal compounds having conjugate aluminoxate anions and their use as catalyst components | ALBEMARLE CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | BRD4 547/4885CREBBP 113/4885NR3C2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.